Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon-alpha 2a in the treatment of anogenital condylomata acuminatum. The Condylomata International Collaborative Study Group.
An earlier study by this group failed to demonstrate significant therapeutic effect of 4 weeks of systemic recombinant interferon (IFN)-alpha 2 monotherapy on anogenital condylomata acuminatum. The present study was undertaken to determine if 3 MIU of IFN given three times weekly for 4 consecutive weeks and starting immediately after CO2 laser ablation of all visible warts would be effective. In a multicenter placebo-controlled randomized double-blinded study of 130 evaluatable patients followed for 36 weeks after treatment, no beneficial effects were noted in terms of complete response (24 placebo vs. 23 IFN patients) and recurrences (38 placebo vs. 46 IFN patients). None of the pretreatment and demographic characteristics affected outcome with statistically significant differences. CO2 laser ablation combined with systemic recombinant IFN-alpha 2 was ineffective in this study as treatment of anogenital condylomata.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001005:Anus Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D010412:Penile Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014625:Vaginal Neoplasms / Q000628:therapy*; D014846:Vulvar Neoplasms / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins